| A phase 3 trial of bevacizumab in ovarian cancer TJ Perren, AM Swart, J Pfisterer, JA Ledermann, E Pujade-Lauraine, ... New England Journal of Medicine 365 (26), 2484-2496, 2011 | 2520 | 2011 |
| Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial S Kehoe, J Hook, M Nankivell, GC Jayson, H Kitchener, T Lopes, ... The Lancet 386 (9990), 249-257, 2015 | 1365 | 2015 |
| Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial AM Oza, AD Cook, J Pfisterer, A Embleton, JA Ledermann, ... The Lancet Oncology 16 (8), 928-936, 2015 | 881 | 2015 |
| Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial TM Suter, M Procter, DJ van Veldhuisen, M Muscholl, J Bergh, ... Journal of clinical oncology 25 (25), 3859-3865, 2007 | 687 | 2007 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 640 | 2017 |
| Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen J Adams, PJ Carder, S Downey, MA Forbes, K MacLennan, V Allgar, ... Cancer research 60 (11), 2898-2905, 2000 | 536 | 2000 |
| Automated collection of quality-of-life data: a comparison of paper and computer touch-screen questionnaires G Velikova, EP Wright, AB Smith, A Cull, A Gould, D Forman, T Perren, ... Journal of clinical oncology 17 (3), 998-998, 1999 | 434 | 1999 |
| Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies RE Banks, AJ Gearing, IK Hemingway, DR Norfolk, TJ Perren, PJ Selby British Journal of Cancer 68 (1), 122-124, 1993 | 401 | 1993 |
| Multiple myeloma treated with high dose intravenous melphalan PJ Selby, TJ McElwain, AC Nandi, TJ Perren, RL Powles, CR Tillyer, ... British journal of haematology 66 (1), 55-62, 1987 | 291 | 1987 |
| Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial P Schmid, J Abraham, S Chan, D Wheatley, AM Brunt, G Nemsadze, ... Journal of Clinical Oncology 38 (5), 423-433, 2020 | 290 | 2020 |
| Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial JA Ledermann, AC Embleton, F Raja, TJ Perren, GC Jayson, GJS Rustin, ... The Lancet 387 (10023), 1066-1074, 2016 | 266 | 2016 |
| Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial JF Smyth, A Bowman, T Perren, P Wilkinson, RJ Prescott, KJ Quinn, ... Annals of oncology 8 (6), 569-573, 1997 | 265 | 1997 |
| Phase III multicenter clinical trial of the sialyl‐TN (STn)‐keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer D Miles, H Roché, M Martin, TJ Perren, DA Cameron, J Glaspy, D Dodwell, ... The oncologist 16 (8), 1092-1100, 2011 | 260 | 2011 |
| Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials I Vergote, C Coens, M Nankivell, GB Kristensen, MKB Parmar, T Ehlen, ... The Lancet Oncology 19 (12), 1680-1687, 2018 | 253 | 2018 |
| Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic … TRJ Evans, A Yellowlees, E Foster, H Earl, DA Cameron, AW Hutcheon, ... Journal of Clinical Oncology 23 (13), 2988-2995, 2005 | 247 | 2005 |
| Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer JA Ledermann, A Hackshaw, S Kaye, G Jayson, H Gabra, I McNeish, ... J Clin Oncol 29 (28), 3798-3804, 2011 | 245 | 2011 |
| The acute phase protein response in patients receiving subcutaneous IL-6 RE Banks, MA Forbes, M Storr, J Higginson, D Thompson, J Raynes, ... Clinical & Experimental Immunology 102 (1), 217-223, 1995 | 190 | 1995 |
| c-erbB-2 oncogene as a prognostic marker in breast cancer. TJ Perren British journal of cancer 63 (3), 328, 1991 | 190 | 1991 |
| Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 … D Stark, M Nankivell, E Pujade-Lauraine, G Kristensen, L Elit, M Stockler, ... The lancet oncology 14 (3), 236-243, 2013 | 189 | 2013 |
| Detection of colorectal cancer cells in peripheral blood by reverse‐transcriptase polymerase chain reaction for cytokeratin 20 DK Wyld, P Selby, TJ Perren, SK Jonas, TG Allen‐Mersh, J Wheeldon, ... International journal of cancer 79 (3), 288-293, 1998 | 188 | 1998 |
JA LedermannProfessor of medical oncology, UCL Cancer InstituteVerified email at ucl.ac.uk
